Journal of Virology, October 1999, p. 8824-8830, Vol. 73, No. 10
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Association of Nef with the Human Immunodeficiency
Virus Type 1 Core
Alexander
Kotov,1
Jing
Zhou,1
Paula
Flicker,2 and
Christopher
Aiken1,*
Department of Microbiology and Immunology,
Vanderbilt University School of Medicine,1 and
Department of Molecular Biology, Vanderbilt
University,2 Nashville, Tennessee
Received 16 February 1999/Accepted 16 June 1999
 |
ABSTRACT |
Highly conserved among primate lentiviruses, the human
immunodeficiency virus type 1 (HIV-1) Nef protein enhances viral
infectivity by an unknown mechanism. Nef-defective virions are blocked
at a stage of the HIV-1 life cycle between entry and reverse
transcription, possibly virus uncoating. Nef is present in purified
HIV-1 particles; however, it has not been determined whether Nef is
specifically recruited into HIV-1 particles or whether
virion-associated Nef plays a functional role in HIV-1 replication. To
address the specificity and potential functionality of
virion-associated Nef, we determined the subviral localization of Nef.
HIV-1 cores were isolated by detergent treatment of concentrated
virions followed by equilibrium density gradient sedimentation.
Relative to HIV-1 virions, HIV-1 cores contained equivalent amounts of
reverse transcriptase and integrase, decreased amounts of the viral
matrix protein, and trace quantities of the viral transmembrane
glycoprotein gp41. Examination of the particles by electron microscopy
revealed cone-shaped structures characteristic of lentiviral cores.
Similar quantities of proteolytically processed Nef protein were
detected in gradient fractions of HIV-1 cores and intact virions. In
addition, detergent-resistant subviral complexes isolated from immature
HIV-1 particles contained similar quantities of Nef as untreated
virions. These results demonstrate that Nef stably associates with the
HIV-1 core and suggest that virion-associated Nef plays a functional
role in accelerating HIV-1 replication.
 |
TEXT |
The accessory protein Nef is
essential for efficient replication and pathogenesis of primate
lentiviruses. Disruption of the nef open reading frame
results in attenuation of simian immunodeficiency virus in rhesus
macaques, and the rapid reversion of point mutations is strong evidence
for a requirement for Nef in virus replication (20). In
human immunodeficiency virus type 1 (HIV-1), the presence of a
functional nef gene stimulates virus replication in culture by a poorly defined mechanism (11, 30, 35). Nef stimulates HIV-1 infectivity by 5- to 50-fold in single-cycle infection assays, and this stimulation has been attributed to enhancement of reverse transcription in target cells (6, 34). Although Nef also downregulates cell surface expression of the HIV-1 receptor CD4 (14), this effect appears to be insufficient to account for HIV-1 infectivity enhancement by Nef (6, 30). A 5- to
10-fold enhancement of HIV-1 infectivity by Nef (Nef phenotype) is
observed when HIV-1 is produced from CD4-negative cells. Furthermore,
pseudotyping HIV-1 particles by the envelope proteins of amphotropic
murine leukemia virus fails to rescue the Nef phenotype when target
cells either express or lack CD4 (6, 31). Additionally, CD4
downregulation and infectivity enhancement are genetically separable
activities of Nef (17). Collectively, these results suggest
a functional independence of CD4 downregulation and Nef-mediated HIV-1
infectivity enhancement. Nef is required for efficient formation of the
earliest reverse transcription products; this suggests that Nef acts at an early step in the virus life cycle prior to reverse transcription (6, 34). The recent observation that pseudotyping HIV-1
particles by the glycoprotein of vesicular stomatitis virus targets
HIV-1 entry to an endocytic route and suppresses the Nef phenotype is also consistent with a role of Nef in postentry events such as uncoating or intracellular transport (3).
Despite the finding that Nef-defective HIV-1 particles resemble
wild-type virions both structurally and biochemically (31), Nef has been detected in HIV-1 particles (8, 32, 38). The presence of Nef within virions was confirmed by the observation that
Nef is a substrate for the viral protease and is cleaved into a small
amino-terminal fragment and a larger carboxy-terminal domain. These
results suggest that Nef may function directly in the HIV-1 particle or
after entry into the target cell. Nevertheless, it remains unclear
whether Nef is specifically recruited into virions and whether
virion-associated Nef plays a functional role in HIV-1 replication. A
key to understanding whether Nef plays a functional role in HIV-1
particles is to determine the localization of Nef within the virion.
Nef is a myristoylated protein and is expected to associate with the
inner face of the viral lipid envelope; alternatively, Nef may
associate with the viral core. To address these issues, we isolated
HIV-1 cores and tested for the presence of Nef.
Isolation of HIV-1 core structures.
HIV-1 cores were isolated
from virions by a modification of the "spin-thru" method previously
described for the purification of HIV-2 cores (21). Filtered
supernatants (30 ml) from 293T cells transfected with the proviral DNA
construct R9 (12) were pelleted through a 4-ml cushion of
20% sucrose (120,000 × g, 3 h), and the pellet
was allowed to dissolve in 0.25 ml of STE buffer (10 mM Tris-HCl [pH
7.4], 100 mM NaCl, 1 mM EDTA) for 2 h at 4°C. Linear density
gradients, prepared by mixing equal volumes of 30 and 70% (wt/vol)
sucrose in STE buffer in a gradient former, were overlaid with 0.25 ml
of 15% sucrose containing 1% Triton X-100. This layer was covered
with a 0.25-ml cushion of STE containing 7.5% sucrose, which served as
a barrier to minimize mixing of the virus and detergent interfaces
before centrifugation. Concentrated HIV-1 particles in STE buffer (0.25 ml) were carefully layered on top of the barrier layer, and tubes were
centrifuged in a Beckman SW-41 rotor (100,000 × g,
16 h, 4°C). Twelve 1-ml fractions were collected from the bottom
of each tube and assayed for reverse transcriptase (RT) activity and
capsid protein (CA) content by an enzyme-linked immunosorbent assay
(ELISA) (36). The density of each fraction was determined by
measurements of refractive index and comparison with a standard series
of sucrose concentrations of predetermined density. Fractions were
collected from the bottom of the tubes and assayed for CA concentration
by ELISA. Detergent treatment of HIV-1 particles resulted in
sedimentation of significant quantities of CA near the bottom of the
gradient (Fig. 1A). The peak of this material corresponded to the
density expected for retroviral cores (1.26 g/ml). In this gradient, a
large quantity of CA, corresponding to free protein released from
solubilized virions, remained in the detergent-containing fractions at
the top of the gradient (Fig. 1A, see
fraction 11). In contrast to the detergent-containing gradient, virions
sedimented through a control sucrose gradient lacking detergent to an
equilibrium density of 1.16 g/ml, which corresponds to the density of
intact retroviral particles (Fig. 1B).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Isolation of HIV-1 core structures by equilibrium
sedimentation through a detergent layer. HIV-1 supernatants were
harvested from 293T cells transiently transfected with the R9 wild-type
HIV-1 proviral plasmid and filtered to remove cellular debris. Virions
were concentrated by ultracentrifugation, resuspended in STE buffer,
and layered onto 30 to 70% linear sucrose gradients containing a layer
of 1% Triton X-100 at the top. The virions were sedimented through the
detergent layer and into the sucrose gradient. Fractions (1 ml) were
collected from the bottom of the gradient and assayed for CA
concentration by ELISA and density by refractometry. The lane numbers
correspond to gradient fractions. (A) Detergent-treated virions; (B)
virions subjected to ultracentrifugation on a control gradient lacking
detergent.
|
|
Biochemical analysis of HIV-1 cores.
To analyze the viral
protein composition of the putative HIV-1 core structures, gradient
fractions of detergent-treated and untreated HIV-1 particles were
subjected to immunoblot analyses after dilution with STE buffer to
reduce the density of the fractions and pelleting by
ultracentrifugation at 100,000 × g. As predicted, the
dense fractions from the detergent-containing gradient contained CA,
which forms the shell of the core (Fig.
2A, upper blot, lanes 1 to 4). In
contrast, the pelletable CA in the fractions of untreated virions was
present only in fractions of lower density (Fig. 2A, lower blot, lanes
6 to 9). To determine whether the dense fractions from the
detergent-containing gradients contained additional HIV-1 proteins
expected to be present in the HIV-1 core, the blot was reprobed with
antisera specific for several HIV-1 structural proteins. In Fig. 2A,
the samples from fraction 3 of the detergent-containing gradient and
fraction 7 of the gradient lacking detergent contained similar
quantities of CA as determined by ELISA prior to loading, and this is
consistent with the CA band intensities on the immunoblots. Upon
reprobing the blot with antisera specific for additional HIV-1
structural proteins, we observed that the densely sedimenting material
from detergent-exposed virions contained a small fraction of the viral
matrix protein (MA) present in intact virions (Fig. 2A). Although MA
was previously reported as a component of the HIV-2 core
(13), our results represent the first demonstration of the
association of MA with the core of HIV-1. MA has been observed in viral
ribonucleoprotein complexes (preintegration complexes) isolated from
cells acutely infected with HIV-1 (9, 28), and it was
therefore anticipated that some MA would be associated with the HIV-1
core. Association of MA with the HIV-1 core may facilitate HIV-1
uncoating or nuclear import of the preintegration complex. HIV-1
maturation is an intricate process, and MA might also regulate the
proper assembly of the HIV-1 core.

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 2.
Immunoblot analysis of isolated HIV-1 cores. Fractions
(1 ml) from sucrose gradients were diluted to 1.5 ml with STE buffer to
reduce the density of the solutions, and the particulate material was
pelleted by ultracentrifugation. Pellets were dissolved in sample
buffer and subjected to immunoblot analysis using various HIV-1
protein-specific antisera. Separate gels containing fractions from
detergent-treated virions and untreated virions were transferred onto a
single polyvinylidene difluoride filter. Blots were developed by
chemiluminescence after probing with the appropriate horseradish
peroxidase-conjugated secondary antiserum. In each panel, the upper
half of the image shows the material isolated from detergent-treated
virions, and the lower part shows control virions isolated in the
absence of detergent. (A) Anti-CA plus anti-MA; (B) anti-RT plus
anti-IN; (C) anti-gp41; (D) anti-Nef. The molecular masses of protein
standards run on the same gel are shown in kilodaltons to the right of
each panel.
|
|
Detergent-treated virions contained similar amounts of reverse
transcriptase (RT) and integrase (IN) as intact virions (Fig.We thank Dean Ballard, Terry Dermody, and Paul Spearman for helpful
comments on the manuscript. The following antisera were obtained
through the NIH AIDS Research and Reference Reagent Program: antiserum
to HIV-1 RT (catalog no. 634) from Division of AIDS, National Institute
of Allergy and Infectious Diseases, and antiserum to HIV-1 IN (catalog
no. 758) from Duane Grandgenett.
This study was funded by NIH grant R01 AI 40363. C.A. was sponsored in
part by an AmFAR/Genetech, Inc., Scholar Award.
| 1.
|
Ahmad, N., and S. Venkatesan.
1988.
Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR.
Science
241:1481-1485[Abstract/Free Full Text].
|
| 2.
|
Aiken, C.
1998.
Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity.
Virology
248:139-147[Medline].
|
| 3.
|
Aiken, C.
1997.
Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.
J. Virol.
71:5871-5877[Abstract].
|
| 4.
| Aiken, C. Unpublished data.
|
| 5.
|
Aiken, C.,
J. Konner,
N. R. Landau,
M. E. Lenburg, and D. Trono.
1994.
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.
Cell
76:853-864[Medline].
|
| 6.
|
Aiken, C., and D. Trono.
1995.
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.
J. Virol.
69:5048-5056[Abstract].
|
| 7.
|
Bess, J. W., Jr.,
R. J. Gorelick,
L. E. Henderson, and L. O. Arthur.
1997.
Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.
Virology
230:134-144[Medline].
|
| 8.
|
Bukovsky, A.,
T. Dorfman,
A. Weimann, and H. G. Gottlinger.
1997.
Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease.
J. Virol.
71:1013-1018[Abstract].
|
| 9.
|
Bukrinsky, M. I.,
N. Sharova,
T. L. McDonald,
T. Pushkarskaya,
W. G. Tarpley, and M. Stevenson.
1993.
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.
Proc. Natl. Acad. Sci. USA
90:6125-6129[Abstract/Free Full Text].
|
| 10.
|
Chen, Y.-L.,
D. Trono, and D. Camaur.
1998.
The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity.
J. Virol.
72:3178-3184[Abstract/Free Full Text].
|
| 11.
|
Chowers, M. Y.,
C. A. Spina,
T. J. Kwoh,
N. J. S. Fitch,
D. D. Richman, and J. C. Guatelli.
1994.
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.
J. Virol.
68:2906-2914[Abstract/Free Full Text].
|
| 12.
|
Gallay, P.,
S. Swingler,
C. Aiken, and D. Trono.
1995.
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator.
Cell
80:379-388[Medline].
|
| 13.
|
Gallay, P.,
S. Swingler,
J. Song,
F. Bushman, and D. Trono.
1995.
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase.
Cell
83:569-576[Medline].
|
| 14.
|
Garcia, J. V., and A. D. Miller.
1991.
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.
Nature
350:508-511[Medline].
|
| 15.
|
Gelderblom, H. R.,
E. H. S. Hausmann,
M. Orzel,
G. Pauli, and M. A. Koch.
1987.
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.
Virology
156:171-176[Medline].
|
| 16.
|
Gluschankof, P.,
I. Mondor,
H. R. Gelderblom, and Q. J. Sattentau.
1997.
Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations.
Virology
230:125-133[Medline].
|
| 17.
|
Goldsmith, M. A.,
M. T. Warmerdam,
R. E. Atchison,
M. D. Miller, and W. C. Greene.
1995.
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef.
J. Virol.
69:4112-4121[Abstract].
|
| 18.
|
Greenberg, M. E.,
S. Bronson,
M. Lock,
M. Neumann,
G. N. Pavlakis, and J. Skowronski.
1997.
Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation.
EMBO J.
16:6964-6976[Medline].
|
| 19.
|
Kaminchik, J.,
N. Bashan,
D. Pinchasi,
B. Amit,
N. Sarver,
M. I. Johnston,
M. Fischer,
Z. Yavin,
M. Gorecki, and A. Panet.
1990.
Expression and biochemical characterization of human immunodeficiency virus type 1 nef gene product.
J. Virol.
65:583-588.
|
| 20.
|
Kestler III, H. W.,
D. J. Ringler,
K. Mori,
D. L. Panicali,
P. K. Sehgal,
M. D. Daniel, and R. C. Desrosiers.
1991.
Importance of the nef gene for maintenance of high virus loads and for development of AIDS.
Cell
65:651-662[Medline].
|
| 21.
|
Kewalramani, V. N., and M. Emerman.
1996.
Vpx association with mature core structures of HIV-2.
Virology
218:159-168[Medline].
|
| 22.
| Kotov, A., and C. Aiken. Unpublished data.
|
| 23.
| Kotov, A., P. Flicker, and C. Aiken. Unpublished
data.
|
| 24.
|
Le Gall, S.,
L. Erdtmann,
S. Benichou,
C. Berlioz-Torrent,
L. Liu,
R. Benarous,
J. M. Heard, and O. Schwartz.
1998.
Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules.
Immunity
8:483-495[Medline].
|
| 25.
|
Luban, J.
1996.
Absconding with the chaperone: essential cyclophilin-Gag interactions in HIV-1 virions.
Cell
87:1157-1159[Medline].
|
| 26.
|
Luo, T.,
J. L. Douglas,
R. L. Livingston, and J. V. Garcia.
1998.
Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems.
Virology
241:224-233[Medline].
|
| 27.
|
Matlin, K. S.,
H. Reggio,
A. Helenius, and K. Simons.
1982.
Pathway of vesicular stomatitis virus entry leading to infection.
J. Mol. Biol.
156:609-631[Medline].
|
| 28.
|
Miller, M. D.,
C. M. Farnet, and F. D. Bushman.
1997.
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition.
J. Virol.
71:5382-5390[Abstract].
|
| 29.
|
Miller, M. D.,
M. T. Warmerdam,
S. S. Ferrell,
R. Benitez, and W. C. Greene.
1997.
Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity.
Virology
234:215-225[Medline].
|
| 30.
|
Miller, M. D.,
M. T. Warmerdam,
I. Gaston,
W. C. Greene, and M. B. Feinberg.
1994.
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.
J. Exp. Med.
179:101-113[Abstract/Free Full Text].
|
| 31.
|
Miller, M. D.,
M. T. Warmerdam,
K. A. Page,
M. B. Feinberg, and W. C. Greene.
1995.
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry.
J. Virol.
69:570-584[Abstract].
|
| 32.
|
Pandori, M. W.,
N. J. S. Fitch,
H. M. Craig,
D. D. Richman,
C. A. Spina, and J. C. Guatelli.
1996.
Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.
J. Virol.
70:4283-4290[Abstract].
|
| 33.
|
Piguet, V.,
Y. L. Chen,
A. Mangasarian,
M. Foti,
J. L. Carpentier, and D. Trono.
1998.
Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes.
EMBO J.
17:2472-2481[Medline].
|
| 34.
|
Schwartz, O.,
V. Marechal,
O. Danos, and J.-M. Heard.
1995.
Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell.
J. Virol.
69:4053-4059[Abstract].
|
| 35.
|
Spina, C. A.,
T. J. Kwoh,
M. Y. Chowers,
J. C. Guatelli, and D. D. Richman.
1994.
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes.
J. Exp. Med.
179:115-123[Abstract/Free Full Text].
|
| 36.
|
Wehrly, K., and B. Chesebro.
1997.
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents.
Methods
12:288-293[Medline].
|
| 37.
|
Welker, R.,
M. Harris,
B. Cardel, and H.-G. Krausslich.
1998.
Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity.
J. Virol.
72:8833-8840[Abstract/Free Full Text].
|
| 38.
|
Welker, R.,
H. Kottler,
H. R. Kalbitzer, and H.-G. Krausslich.
1996.
Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase.
Virology
219:228-236[Medline].
|
| 39.
|
Wiegers, K.,
G. Rutter,
H. Kottler,
U. Tessmer,
H. Hohenberg, and H.-G. Krausslich.
1998.
Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.
J. Virol.
72:2846-2854[Abstract/Free Full Text].
|
| 40.
| Zhou, J., and C. Aiken. Unpublished data.
|
| 41.
|
Zhou, W., and M. D. Resh.
1996.
Differential membrane binding of the human immunodeficiency virus type 1 matrix protein.
J. Virol.
70:8540-8548[Abstract].
|